Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 02 2021
23 02 2021
Historique:
received:
18
02
2020
accepted:
01
02
2021
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
1
12
2021
Statut:
epublish
Résumé
Corneal haze post refractive surgery is prevented by mitomycin c (MMC) treatment though it can lead to corneal endothelial damage, persistent epithelial defects and necrosis of cells. Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects. For clinical application we have investigated the short and long term outcome of cells exposed to SAHA. Human donor cornea, cultured limbal epithelial cells, corneal rims and lenticules were incubated with SAHA and MMC. The cells/tissue was then analyzed by RT-qPCR, immunofluorescence and western blot for markers of apoptosis and fibrosis. The results reveal that short term exposure of SAHA and SAHA + MMC reduced apoptosis levels and increased αSMA expression compared to those treated with MMC. Epithelial cells derived from cultured corneal rim that were incubated with the MMC, SAHA or MMC + SAHA revealed enhanced apoptosis, reduced levels of CK3/CK12, ∆NP63 and COL4A compared to other treatments. In SAHA treated lenticules TGFβ induced fibrosis was reduced. The results imply that MMC treatment for corneal haze has both short term and long term adverse effects on cells and the cellular properties. However, a combinatorial treatment of SAHA + MMC prevents expression of corneal fibrotic markers without causing any adverse effect on cellular properties.
Identifiants
pubmed: 33623133
doi: 10.1038/s41598-021-83881-y
pii: 10.1038/s41598-021-83881-y
pmc: PMC7902619
doi:
Substances chimiques
Collagen Type IV
0
Mitomycin
50SG953SK6
Vorinostat
58IFB293JI
Keratins
68238-35-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4392Références
J Ocul Pharmacol Ther. 2004 Apr;20(2):129-38
pubmed: 15117569
Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1260-4
pubmed: 11587609
Surv Ophthalmol. 2009 Jul-Aug;54(4):487-502
pubmed: 19539836
Biochem Pharmacol. 1987 Oct 1;36(19):3115-20
pubmed: 3117061
J Cell Biochem. 2006 May 15;98(2):409-20
pubmed: 16440322
J Refract Surg. 2009 Oct;25(10):894-7
pubmed: 19835330
Pharmacogenet Genomics. 2011 Mar;21(3):152-61
pubmed: 20216335
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2421-2429
pubmed: 28448670
Science. 1964 Jul 3;145(3627):55-8
pubmed: 14162693
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):103-9
pubmed: 10634608
J Cataract Refract Surg. 2001 Nov;27(11):1840-6
pubmed: 11709259
Ophthalmology. 2015 Jun;122(6):1085-95
pubmed: 25795477
Transl Vis Sci Technol. 2018 Jan 3;8(1):2
pubmed: 30627477
Mol Vis. 2012;18:1828-39
pubmed: 22815636
J Refract Surg. 2012 Apr;28(4):285-90
pubmed: 22386369
Int Ophthalmol. 2018 Jun;38(3):1211-1217
pubmed: 28612330
Iran Biomed J. 2015;19(2):69-75
pubmed: 25864810
Cell Tissue Res. 2018 Dec;374(3):439-453
pubmed: 30284084
Ophthalmology. 2010 Mar;117(3):431-7
pubmed: 20060167
Arch Ophthalmol. 2002 Nov;120(11):1585-6
pubmed: 12427079
Invest Ophthalmol Vis Sci. 1997 Sep;38(10):1998-2007
pubmed: 9331263
Cancer Res. 1996 Mar 1;56(5):988-94
pubmed: 8640791
Vet Ophthalmol. 2016 Nov;19(6):480-487
pubmed: 26559782
J Drug Target. 2007 Aug-Sep;15(7-8):518-30
pubmed: 17671898
Cytotherapy. 2016 Apr;18(4):546-61
pubmed: 26971683
J Curr Ophthalmol. 2017 Sep 27;30(1):3-22
pubmed: 29564404
J Biol Chem. 2011 May 6;286(18):16101-8
pubmed: 21454553
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):28
pubmed: 32084275
Oncol Lett. 2019 Jul;18(1):63-71
pubmed: 31289473
AAPS J. 2005 May 11;7(1):E118-33
pubmed: 16146333
Eye (Lond). 1987;1 ( Pt 2):175-83
pubmed: 3308525
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):2978-84
pubmed: 15326110
Sci Rep. 2019 Nov 18;9(1):16980
pubmed: 31740714
J Refract Surg. 2007 Nov;23(9 Suppl):S1011-4
pubmed: 18046999
Am J Ophthalmol. 2012 Jan;153(1):17-23.e1
pubmed: 21864828
J Invest Dermatol. 2001 Aug;117(2):333-40
pubmed: 11511312
Mol Cancer. 2013 May 24;12:47
pubmed: 23705854
J Cataract Refract Surg. 2006 Sep;32(9):1573-8
pubmed: 16931277
Cancer Res. 1990 Aug 1;50(15):4692-7
pubmed: 2114946
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3381-9
pubmed: 27367506
Cornea. 1998 Nov;17(6):627-39
pubmed: 9820944
Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70
pubmed: 19700647
Cancer Treat Rev. 1976 Sep;3(3):121-39
pubmed: 786455
J Refract Surg. 2017 Dec 1;33(12):834-839
pubmed: 29227512
Oncogene. 2007 Feb 26;26(9):1351-6
pubmed: 17322921
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4837-43
pubmed: 18658091
Laryngoscope. 2003 Feb;113(2):237-42
pubmed: 12567075
Vet Ophthalmol. 2012 Sep;15(5):307-14
pubmed: 22212187
Acta Ophthalmol. 2012 May;90(3):271-6
pubmed: 20456254
Cancer Res. 1985 Aug;45(8):3510-6
pubmed: 3926301
Exp Eye Res. 2014 Apr;121:178-93
pubmed: 24607489
J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
pubmed: 10944550
Vet Ophthalmol. 2010 Jan;13(1):37-42
pubmed: 20149174
J Cataract Refract Surg. 2004 Aug;30(8):1742-50
pubmed: 15313301
Ophthalmology. 2000 Jul;107(7):1235-45
pubmed: 10889092
G3 (Bethesda). 2015 Nov 12;6(1):133-40
pubmed: 26564951
Semin Ophthalmol. 2003 Mar;18(1):2-10
pubmed: 12759854
Exp Eye Res. 2016 Jan;142:110-8
pubmed: 26675407
Anticancer Drugs. 1990 Oct;1(1):5-13
pubmed: 2131038
J Cataract Refract Surg. 2006 Oct;32(10):1741-7
pubmed: 17010877
Sci Rep. 2019 Sep 25;9(1):13905
pubmed: 31554858
Cell Cycle. 2012 Aug 15;11(16):3132-40
pubmed: 22871735
Mutat Res. 1985 Mar;149(1):41-50
pubmed: 3919293
J Mol Med (Berl). 2019 Oct;97(10):1477-1489
pubmed: 31399750
Mol Vis. 2015 Jul 31;21:828-45
pubmed: 26283864
Vet Ophthalmol. 2011 Sep;14(5):304-12
pubmed: 21929607
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5589-5598
pubmed: 30480706
J Cell Mol Med. 2012 Jun;16(6):1245-59
pubmed: 21801304
Mol Vis. 2008 Sep 15;14:1705-12
pubmed: 18806879
Adv Ther. 2019 Apr;36(4):786-797
pubmed: 30859502
Ophthalmology. 2000 Jan;107(1):89-94
pubmed: 10647725
Prog Retin Eye Res. 2017 Sep;60:44-65
pubmed: 28807717
Prog Retin Eye Res. 2015 Nov;49:17-45
pubmed: 26197361
Vet Ophthalmol. 2014 Jul;17 Suppl 1:61-8
pubmed: 25126665
Exp Ther Med. 2016 Nov;12(5):2827-2834
pubmed: 27882081
Anat Rec (Hoboken). 2020 Jun;303(6):1689-1702
pubmed: 30768772
J Refract Surg. 2006 Jun;22(6):562-74
pubmed: 16805119
J Curr Glaucoma Pract. 2019 Jan-Apr;13(1):37-41
pubmed: 31496560
Mutat Res. 2010 Mar 1;685(1-2):38-44
pubmed: 19941876
J Ophthalmic Vis Res. 2011 Jan;6(1):8-12
pubmed: 22454700
Indian J Ophthalmol. 2018 Feb;66(2):190-194
pubmed: 29380756
Clin Cancer Res. 1997 Aug;3(8):1339-46
pubmed: 9815817
In Vivo. 2007 Jan-Feb;21(1):123-32
pubmed: 17354625
PLoS Genet. 2010 Feb 19;6(2):e1000850
pubmed: 20174566
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4661-4669
pubmed: 31725165
Eye Vis (Lond). 2015 Mar 01;2:6
pubmed: 26605362
Br J Ophthalmol. 1994 May;78(5):401-8
pubmed: 8025077
Expert Opin Drug Saf. 2007 Jan;6(1):27-32
pubmed: 17181449
Curr Eye Res. 2014 Apr;39(4):348-58
pubmed: 24401036
Cancer Res. 1984 Dec;44(12 Pt 1):5880-5
pubmed: 6437674
Arch Pharm Res. 2010 Aug;33(8):1261-7
pubmed: 20803130